Developer docs
API playgroundTry for free, no card

Search company profiles

Theranexus

Full company profile

uuid0006bui

Namestring
Theranexus
Legal namestring
Theranexus
Websiteurl
theranexus.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Theranexus (trading as THX Pharma) is a French clinical-stage biopharmaceutical company founded in 2013 as a spin-off of the CEA (Commissariat à l'énergie atomique et aux énergies alternatives), headquartered in Fontenay-aux-Roses in the Paris metropolitan area. The company is publicly listed on Euronext Growth Paris under ticker ALTHX and operates with a small team of 11–50 employees.

Theranexus focuses exclusively on rare neurological diseases where therapeutic options remain limited. Its research department employs an antisense oligonucleotide (ASO) platform — an agile, evolving technological foundation that designs drug candidates capable of precisely targeting disease mechanisms. The current disclosed pipeline comprises four drug candidates targeting five rare diseases, with three named lead programs: an ASO candidate for juvenile Batten disease (CLN3 form), an ASO candidate for Niemann-Pick type C disease, and an ASO candidate for Gaucher disease. The company protects this portfolio with three patent families covering the platform and individual candidates.

Theranexus has no commercialized products and consequently no material product revenue at present. Its stated revenue model is licensing and royalties, with the company positioned to monetize candidates through co-development partnerships, licensing agreements, and eventually commercialization — likely via specialty and hospital pharmacy channels and partnerships with larger pharmaceutical companies. GTM motion is sales-led and oriented toward out-licensing or partnership with major pharma for late-stage development and global reach. A core institutional partnership with CEA underpins the company's access to scientific infrastructure and innovation pipeline.

Short descriptiontext

Theranexus is a French clinical-stage biopharmaceutical company (THX Pharma) that designs antisense oligonucleotide drug candidates for rare neurological diseases, with four candidates in development targeting five indications including CLN3 Batten, Niemann-Pick C, and Gaucher.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, antisense oligonucleotide drugs, neurological disease treatments, biopharmaceutical development, clinical-stage pharmaceuticals
Industry1 code
PRIMARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Rare Disease Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Licensing
TypeLicensing Royalties
Description

As a biopharmaceutical company in the development stage with 4 drug candidates in its pipeline, Theranexus generates revenue through potential licensing agreements, co-development partnerships, and eventual commercialization of its therapeutic candidates for rare neurological diseases.

thxpharma.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Theranexus (THX Pharma) is a clinical-stage biopharmaceutical company developing antisense oligonucleotide-based drug candidates for rare neurological diseases. The company has 4 drug candidates in its pipeline targeting 5 diseases, with named programs for juvenile Batten disease (CLN3 form), Niemann-Pick type C disease, and Gaucher disease. The company is pre-commercial and intends to monetize its pipeline through licensing, co-development partnerships, and eventual commercialization of therapeutic candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 4 drug candidates in clinical development pipeline targeting 5 rare neurological diseases
Product overview1 text field

THX Pharma (Theranexus) is a biopharmaceutical company developing antisense oligonucleotide-based drug candidates for rare neurological diseases. The company has 4 drug candidates in development targeting 5 diseases, including programs for Batten disease (CLN3), Niemann-Pick C disease, and Gaucher disease. Founded in 2013 and spun out from CEA, the company leverages an agile technological platform to design drug candidates that precisely target disease mechanisms and transform scientific innovation into concrete advances for patients.

Product and service3 records
1Drug Candidate for Batten Disease (CLN3)
CategoryRare neurological disease therapeutics
2Drug Candidate for Niemann-Pick C Disease
CategoryRare neurological disease therapeutics
3Drug Candidate for Gaucher Disease
CategoryRare neurological disease therapeutics
Description

Antisense oligonucleotide drug candidate for Gaucher disease, a rare genetic disease with multiple manifestations and variable progression, addressing the importance of developing new therapeutic approaches tailored to patient needs.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Theranexus originated from CEA (Commissariat à l'énergie atomique et aux énergies alternatives), the French Alternative Energies and Atomic Energy Commission. This institutional partnership provides access to scientific expertise, research infrastructure, and a pipeline of innovations for the company.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeOthers
TypeEmerging player
Description

Historical developer of therapies for Niemann-Pick C and other rare neurological diseases. Comparable focus on the same indication despite differing modalities.

TypeBroad incumbent
Description

Large biopharma with significant rare disease portfolio and active oligonucleotide / gene therapy programs. Potential licensing partner and broad competitor for rare disease assets.

TypeBroad incumbent
Description

Established leader in RNA-targeted therapeutics with broad oligonucleotide platform. Comparable in modality and rare disease focus, but operates at much greater scale and commercial maturity.

TypeDirect peer
Description

Clinical-stage company developing stereopure antisense oligonucleotides for rare neurological diseases including Huntington's. Closely comparable modality and indication focus.

TypeDirect peer
Description

Pioneer of antisense oligonucleotide therapeutics with a broad pipeline including CNS and rare disease programs. Directly comparable as an antisense platform developer targeting neurological indications.

TypeDirect peer
Description

Leader in RNA-targeted therapeutics for rare neurological and neuromuscular diseases. Highly comparable given shared antisense/RNA modality and rare disease focus.

TypeEmerging player
Description

Clinical-stage company developing antisense oligonucleotide-based therapies for severe genetic diseases including CNS indications. Comparable as a smaller oligonucleotide-focused peer targeting rare diseases.

TypeDirect peer
Description

Specialty rare disease biopharma with active programs in Niemann-Pick C and other genetic conditions. Direct competitor for Theranexus's Niemann-Pick C candidate.

TypeEmerging player
Description

Clinical-stage company developing treatments for Niemann-Pick Type C disease. Direct overlap with one of Theranexus's primary pipeline indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Theranexus

Rare Disease Therapeuticstheranexus.com

Theranexus is a French clinical-stage biopharmaceutical company (THX Pharma) that designs antisense oligonucleotide drug candidates for rare neurological diseases, with four candidates in development targeting five indications including CLN3 Batten, Niemann-Pick C, and Gaucher.

What Theranexus does

Theranexus (trading as THX Pharma) is a French clinical-stage biopharmaceutical company founded in 2013 as a spin-off of the CEA (Commissariat à l'énergie atomique et aux énergies alternatives), headquartered in Fontenay-aux-Roses in the Paris metropolitan area. The company is publicly listed on Euronext Growth Paris under ticker ALTHX and operates with a small team of 11–50 employees.

Theranexus focuses exclusively on rare neurological diseases where therapeutic options remain limited. Its research department employs an antisense oligonucleotide (ASO) platform — an agile, evolving technological foundation that designs drug candidates capable of precisely targeting disease mechanisms. The current disclosed pipeline comprises four drug candidates targeting five rare diseases, with three named lead programs: an ASO candidate for juvenile Batten disease (CLN3 form), an ASO candidate for Niemann-Pick type C disease, and an ASO candidate for Gaucher disease. The company protects this portfolio with three patent families covering the platform and individual candidates.

Theranexus has no commercialized products and consequently no material product revenue at present. Its stated revenue model is licensing and royalties, with the company positioned to monetize candidates through co-development partnerships, licensing agreements, and eventually commercialization — likely via specialty and hospital pharmacy channels and partnerships with larger pharmaceutical companies. GTM motion is sales-led and oriented toward out-licensing or partnership with major pharma for late-stage development and global reach. A core institutional partnership with CEA underpins the company's access to scientific infrastructure and innovation pipeline.

Theranexus firmographics

Firmographics
Name
Theranexus
Legal name
Theranexus
Website
https://theranexus.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Theranexus is a French clinical-stage biopharmaceutical company (THX Pharma) that designs antisense oligonucleotide drug candidates for rare neurological diseases, with four candidates in development targeting five indications including CLN3 Batten, Niemann-Pick C, and Gaucher.
Ownership category
akta.pro rank

Theranexus industry classification

Industry
Product category
Rare Disease Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Antisense oligonucleotide drugs
  • Neurological disease treatments
  • Biopharmaceutical development
  • Clinical-stage pharmaceuticals

Where Theranexus is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Theranexus business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Licensing: As a biopharmaceutical company in the development stage with 4 drug candidates in its pipeline, Theranexus generates revenue through potential licensing agreements, co-development partnerships, and eventual commercialization of its therapeutic candidates for rare neurological diseases.

Go-to-market motion1 record

Marketing channels1 record

Theranexus product offering

Product offering

Core offering

Theranexus (THX Pharma) is a clinical-stage biopharmaceutical company developing antisense oligonucleotide-based drug candidates for rare neurological diseases. The company has 4 drug candidates in its pipeline targeting 5 diseases, with named programs for juvenile Batten disease (CLN3 form), Niemann-Pick type C disease, and Gaucher disease. The company is pre-commercial and intends to monetize its pipeline through licensing, co-development partnerships, and eventual commercialization of therapeutic candidates.

Product overview

THX Pharma (Theranexus) is a biopharmaceutical company developing antisense oligonucleotide-based drug candidates for rare neurological diseases. The company has 4 drug candidates in development targeting 5 diseases, including programs for Batten disease (CLN3), Niemann-Pick C disease, and Gaucher disease. Founded in 2013 and spun out from CEA, the company leverages an agile technological platform to design drug candidates that precisely target disease mechanisms and transform scientific innovation into concrete advances for patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug Candidate for Batten Disease (CLN3)
  • Drug Candidate for Niemann-Pick C Disease
  • Drug Candidate for Gaucher Disease Antisense oligonucleotide drug candidate for Gaucher disease, a rare genetic disease with multiple manifestations and variable progression, addressing the importance of developing new therapeutic approaches tailored to patient needs.

Quantifiable outcome

  • 4 drug candidates in clinical development pipeline targeting 5 rare neurological diseases

Companies that use Theranexus

Customer profile

Segments3 records

Ideal customer profiles2 records

Theranexus technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Theranexus partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CEA (French Alternative Energies and Atomic Energy Commission)coreStrategic or Co-development PartnerTheranexus originated from CEA (Commissariat à l'énergie atomique et aux énergies alternatives), the French Alternative Energies and Atomic Energy Commission. This institutional partnership provides access to scientific expertise, research infrastructure, and a pipeline of innovations for the company.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Theranexus competitors and assessment

Company assessment

Others

Emerging players

  • Orphazyme: Historical developer of therapies for Niemann-Pick C and other rare neurological diseases. Comparable focus on the same indication despite differing modalities.
  • Stoke Therapeutics: Clinical-stage company developing antisense oligonucleotide-based therapies for severe genetic diseases including CNS indications. Comparable as a smaller oligonucleotide-focused peer targeting rare diseases.
  • Cycle Therapeutics (Cyclo): Clinical-stage company developing treatments for Niemann-Pick Type C disease. Direct overlap with one of Theranexus's primary pipeline indications.

Broad incumbents

  • Pfizer: Large biopharma with significant rare disease portfolio and active oligonucleotide / gene therapy programs. Potential licensing partner and broad competitor for rare disease assets.
  • Alnylam Pharmaceuticals: Established leader in RNA-targeted therapeutics with broad oligonucleotide platform. Comparable in modality and rare disease focus, but operates at much greater scale and commercial maturity.

Direct peers

  • Wave Life Sciences: Clinical-stage company developing stereopure antisense oligonucleotides for rare neurological diseases including Huntington's. Closely comparable modality and indication focus.
  • Ionis Pharmaceuticals: Pioneer of antisense oligonucleotide therapeutics with a broad pipeline including CNS and rare disease programs. Directly comparable as an antisense platform developer targeting neurological indications.
  • Sarepta Therapeutics: Leader in RNA-targeted therapeutics for rare neurological and neuromuscular diseases. Highly comparable given shared antisense/RNA modality and rare disease focus.
  • BioMarin Pharmaceutical: Specialty rare disease biopharma with active programs in Niemann-Pick C and other genetic conditions. Direct competitor for Theranexus's Niemann-Pick C candidate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Theranexus social profiles

Digital presence

Theranexus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Theranexus leadership team

Management profile

Number of profiles

Profiles4 records

Theranexus funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Theranexus M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Theranexus

What does Theranexus do?

Theranexus (THX Pharma) is a clinical-stage biopharmaceutical company developing antisense oligonucleotide-based drug candidates for rare neurological diseases. The company has 4 drug candidates in its pipeline targeting 5 diseases, with named programs for juvenile Batten disease (CLN3 form), Niemann-Pick type C disease, and Gaucher disease. The company is pre-commercial and intends to monetize its pipeline through licensing, co-development partnerships, and eventual commercialization of therapeutic candidates.

Is Theranexus a public or private company?

Theranexus is a public company. It is classified as public and is currently operating.

When was Theranexus founded?

Theranexus was founded in 2013. It employs 11 to 50 people.

Where is Theranexus based?

Theranexus is headquartered in Lyon, France, in the Europe region.

How does Theranexus make money?

One revenue line is on record: drug Development and Licensing.

Who are Theranexus's main competitors?

Roche is listed as an others. Emerging players are Orphazyme, Stoke Therapeutics and Cycle Therapeutics (Cyclo). Broad incumbents are Pfizer and Alnylam Pharmaceuticals. Direct peers are Wave Life Sciences, Ionis Pharmaceuticals, Sarepta Therapeutics and BioMarin Pharmaceutical.

Does Theranexus have an API?

No public API is recorded for Theranexus.

What industry is Theranexus in?

Theranexus's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Globe and MailBatten Disease Pipeline 2025: Innovative Clinical Developments by 10+ Global Leaders – DelveInsight | Featuring Polaryx Therapeutics, Neurogene, Theranexus, M6P Therapeutics, RegenxbioDelveInsight's 2025 Batten Disease pipeline report profiles over 10 companies developing more than 12 therapeutic candidates. The FDA approved Brineura (cerliponase alfa) in 2017 for CLN2 disease, with its indication expanded in July 2024 to all ages. The report also highlights pipeline drugs like PLX-200 and NGN-101.PR NewswireBatten Disease Drug Pipeline Market Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline DrugsResearchAndMarkets.com released a market report in January 2023 providing comprehensive insights into the Batten Disease drug pipeline, covering more than 10 companies and 10 pipeline drugs across various stages of clinical development from preclinical to Phase III. The report highlights key drug candidates including PLX-200 (Polaryx Therapeutics) which received FDA Fast Track designation in August 2020 for Juvenile Infantile Neuronal Ceroid Lipofuscinosis, as well as TSHA-118 (Taysha Gene Therapies) for CLN1 disease and LX1004 (Lexeo Therapeutics) for Neuronal ceroid lipofuscinosis. The assessment identifies approximately 10 key companies working on Batten Disease therapies, including Recursion Pharmaceuticals, Neurogene Inc, and Theranexus, with Polaryx Therapeutics' PLX-200 being the most advanced candidate in Phase III development.PrwebThe Quinism Foundation Shares its Concerns with Theranexus Regarding its Drug Candidate THN201The Quinism Foundation sent a letter to Theranexus expressing concerns about its Alzheimer's drug candidate THN201, which combines donepezil and mefloquine. The foundation cites EMA warnings that mefloquine can cause persistent neuropsychiatric effects, including nightmares and cognitive impairment. It urged Theranexus to review clinical protocols and discontinue the drug if subjects report such symptoms.